Nanomerics will be attend the One-on-one partnering at Bio2013 in Chicago. Nanomerics will be discussing new products in the area of pain, infection, oncology, and anti-inflammation for oral, nasal, and ophthalmological use. Nanomerics will also be discussing how we partner our MET system for the delivery of partners' drugs or peptides via the oral or nasal route, as well as for delivery to the eye and across the BBB.
Nanomerics CSO Prof IF Uchegbu reviews the state of play in the nanomedicines area.
She discusses the progress of the field since the pioneering days of Doxil and Ambisome - and the new generation of nanomedicines making their way into the clinic; for example Nanomerics' MET technology.
Nanomerics' CSO Ijeoma Uchegbu today addresses the GPEN (Globalization of Pharmaceutics Education Network) meeting 2012 in Melbourne and talk about "Delivering challenging molecules across biological barriers'.
Professor Ijeoma Uchegbu will be presenting within the Next Generation session at Biopharm America 2012. Biopharm America's Next Generation session is reserved for exciting new technology companies. Within this presentation Professor Uchegbu will highlight the benefits of Nanomerics' Molecular Envelope Technology (MET) and present a number of case studies.
Nanomerics is pleased to announce signing of a collaboration agreement with UCL School of Pharmacy, the University of Exeter Physics Department and AMTechnoloy. The £1.2M research contract will fund pharmacological and drug development research on Nanomerics pain therapeutic - METDoloron. METDoloron is an oral peptide pain therapeutic enabled by
Nanomerics and UCL School of Pharmacy scientists announce delivery of a hydrophylic peptide across the blood-brain-barrier (BBB). The BBB prevents transport of most drugs from the blood into the brain. By using a pro-drug approach combined with Nanomerics' MET system the group were able to show that the endogenous anti-pain peptide can be carried across this barrier to provide analgesic activity.
Nanomerics today announced publication of a scientific paper which helps to elucidate the some of the mechanisms involved in the efficient oral peptide delivery seen with its MET system.
A new publication reports for the first time how orally administered chitosan nanoparticles (Nanomerics' MET system) are taken up directly via enterocytes.
Nanomerics will be attend the One-on-one partnering at Bio2013 in Chicago. Nanomerics will be discussing new products in the area of pain, infection, oncology, and anti-inflammation for oral, nasal, and ophthalmological use. Nanomerics will also be discussing how we partner our MET system for the delivery of partners' drugs or peptides via the oral or nasal route, as well as for delivery to the eye and across the BBB.
Nanomerics CSO Prof IF Uchegbu reviews the state of play in the nanomedicines area.
Nanomerics' CSO Ijeoma Uchegbu today addresses the GPEN (Globalization of Pharmaceutics Education Network) meeting 2012 in Melbourne and talk about "Delivering challenging molecules across biological barriers'.
Professor Ijeoma Uchegbu will be presenting within the Next Generation session at Biopharm America 2012. Biopharm America's Next Generation session is reserved for exciting new technology companies. Within this presentation Professor Uchegbu will highlight the benefits of Nanomerics' Molecular Envelope Technology (MET) and present a number of case studies.
Nanomerics is pleased to announce signing of a collaboration agreement with UCL School of Pharmacy, the University of Exeter Physics Department and AMTechnoloy. The £1.2M research contract will fund pharmacological and drug development research on Nanomerics pain therapeutic - METDoloron. METDoloron is an oral peptide pain therapeutic enabled by
Nanomerics and UCL School of Pharmacy scientists announce delivery of a hydrophylic peptide across the blood-brain-barrier (BBB). The BBB prevents transport of most drugs from the blood into the brain. By using a pro-drug approach combined with Nanomerics' MET system the group were able to show that the endogenous anti-pain peptide can be carried across this barrier to provide analgesic activity.
For the first time, we present images of naked and empty MET particles imaged in vivo after intravenous administration.
